Artal Group S.A. Karuna Therapeutics, Inc. Transaction History

Artal Group S.A.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$161.33 - $204.36 $23.9 Million - $30.3 Million	-148,253 Reduced 98.84%	1,747 $317,000
Q4 2022 Feb 13, 2023	BUY	$191.53 - $236.82 $4.79 Million - $5.92 Million	25,000 Added 20.0%	150,000 $29.5 Million
Q3 2022 Nov 14, 2022	BUY	$123.79 - $277.42 $15.5 Million - $34.7 Million	125,000 New	125,000 $28.1 Million
Q1 2020 May 14, 2020	SELL	$60.41 - $115.92 $3.02 Million - $5.8 Million	-50,000 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$11.44 - $123.99 $572,000 - $6.2 Million	50,000 New	50,000 $3.77 Million

332K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.